Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Summary
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects. The safety and tolerability of HDM1002 with repaglinide, atorvastatin, digoxin and rosuvastatin when given separately or together will also be evaluated.
Official title: A Phase I, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Effect of Repeated Administration of HDM1002 on the Pharmacokinetics of Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy and Overweight Adult Chinese Subjects
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-10
Completion Date
2025-04
Last Updated
2024-09-23
Healthy Volunteers
Yes
Conditions
Interventions
Repaglinide
Single dose; Administered orally
Atorvastatin
Single dose; Administered orally
Digoxin
Single dose; Administered orally
Rosuvastatin
Single dose; Administered orally
HDM1002
Administered orally
Locations (1)
Peking University Third Hospital
Beijing, China